A dry powder inhaler formulation based on Formoterol Fumarate has been recently approved by the Health Authorities of Cyprus and is under registration in other European countries.
The formulation contains 6 mcg. and 12 mcg. of metered doses, equivalent to respectively 4.5 mcg. and 9 mcg. of delivered doses, and is dispensed through the multidose DPI MIAT-Haler®.
MIAT-Haler® is the patented inhaler whose beneficial owner is Andi-Ventis Ltd. (joint-venture between Medochemie Ltd. and MIAT SpA) which, in a dedicated plant located in Limassol (Cyprus), is developing and producing different formulations of corticosteroids and LABAs for the treatment of respiratory deseases.
